What are the groups of gadolinium-based MRI contrast agents and which agents belong to each group?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 11, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Gadolinium-Based Contrast Agent Classification

Gadolinium-based contrast agents (GBCAs) are classified into three groups by the American College of Radiology based on their association with nephrogenic systemic fibrosis (NSF) risk 1.

Group I: High NSF Risk (No Longer Available in US)

These linear agents were linked to nearly all unconfounded NSF cases and have been withdrawn from the US market 1:

  • Gadodiamide
  • Gadoversetamide
  • Gadopentetate dimeglumine

These agents had the lowest thermodynamic and kinetic stability, making them most susceptible to releasing free gadolinium through transmetallation 2.

Group II: Low NSF Risk

Few, if any, unconfounded cases of NSF have been associated with Group II agents 1. This group includes:

Linear ionic agent:

  • Gadobenate dimeglumine (MultiHance)

Macrocyclic agents:

  • Gadoterate meglumine (Dotarem, Clariscan)
  • Gadobutrol (Gadavist)
  • Gadoteridol (ProHance)

The macrocyclic structure provides superior stability compared to linear agents, with lower propensity for gadolinium dissociation 1, 2. Between 2017-2018, only a single unconfounded case of fibrosing dermopathy was reported with gadobenate dimeglumine in a patient with Stage 2 CKD 3.

Group III: Low NSF Risk

  • Gadoxetate disodium (Eovist/Primovist) - approximately 5% hepatobiliary excretion 1

This agent also has minimal NSF association 3.

Structural Classification

GBCAs can alternatively be categorized by chemical structure 4, 5:

By chelate structure:

  • Macrocyclic (cage-like structure): Higher stability, lower gadolinium deposition
  • Linear (open-chain structure): Lower stability, higher gadolinium deposition

By charge:

  • Ionic: Generally higher stability
  • Nonionic: Lower stability

By biodistribution:

  • Extracellular space agents: Most GBCAs
  • Target/specific agents: Hepatobiliary agents (gadoxetate, gadobenate)
  • Blood-pool agents: Specialized applications

The ACR Group II and III classification is the clinically relevant framework for NSF risk stratification and should guide agent selection in patients with kidney disease 1, 6.

Related Questions

In a patient with a traumatic hip injury, should I order a contrast‑enhanced MRI (gadolinium) or a standard non‑contrast MRI?
Should zinc supplementation be avoided prior to a gadolinium-enhanced magnetic resonance imaging (MRI) scan?
How should I evaluate and manage a patient who develops persistent headache, fatigue, bone pain, or skin changes within weeks after receiving a gadolinium‑based contrast agent (GBCA) for MRI?
How should mild nausea after gadolinium-based contrast MRI be managed?
Which MRI gadolinium-based contrast agent is least toxic for a patient with recent acute kidney injury?
What is the nerve supply of the pleura?
Should an elderly patient be given Ativan (lorazepam) 0.25 mg every 8 hours as needed for behavioral disturbance and rage?
For a patient with a subtle lucency through the dorsal aspect of the fourth middle phalanx epiphysis seen only on lateral radiograph, indicating a nondisplaced fracture, should this be referred to plastic surgery or can it be managed in primary care with splinting?
Can a lactating mother safely receive chlorpheniramine injection (Avil) while breastfeeding her 11‑month‑old infant?
What is the recommended treatment for atopic dermatitis behind the ears with a fungal component?
What are the Canadian Psychiatric Association's guidelines for monitoring antipsychotic therapy, including baseline assessments, laboratory and electrocardiogram monitoring, extrapyramidal symptom evaluation, and clozapine-specific white‑blood‑cell monitoring?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.